First Tracks Biotherapeutics (TRAX) Q3 2026 earnings summary

Executive summary

• Q3 2026 net loss narrowed to $31.4M from $41.9M as operating expenses declined.

• ANB033 Cohort 1 showed statistically significant protection against gluten-induced intestinal damage and symptoms, with no serious or severe adverse events reported.

• October private placement raised $200M gross; pro forma cash was $343M.

Financial highlights

• Q3 R&D expense was $23.8M vs. $33.3M; G&A was $9.0M vs. $11.7M; total operating expenses were $32.8M vs. $45.1M.

• Q3 net loss was $31.4M, or $0.88/share, vs. $41.9M, or $1.50/share; interest income was $1.5M vs. $3.2M.

• 9M R&D expense was $83.4M vs. $114.1M; G&A was $37.1M vs. $28.2M; net loss was $115.2M, or $3.25/share, vs. $131.5M, or $4.52/share.

• Cash and cash equivalents were $155.6M and short-term investments were $73.4M at Sept. 30; pro forma cash after the October placement was $343M.

• 9M operating cash use was $81.5M; investing activities provided $35.0M and financing activities used $36.0M.

Outlook and guidance

• Celiac Cohort 2 top-line data are anticipated in Q1 2027; late-stage trial initiation is anticipated in 2027, pending regulatory discussions.

• EoE Phase 1b top-line data are anticipated in Q3 2027; Phase 2 development in vitiligo and one additional indication is planned for H1 2027.

• Significant expenses and operating losses are expected to continue; existing cash, cash equivalents and investments were expected to fund the operating plan for at least 12 months from financial statement issuance.

• Additional financing may be pursued through equity or debt, collaborations or partnerships; availability and terms are uncertain.